The CRASH-3 Results and News

The CRASH-3 Results and News

After 7 years of international collaboration, we are delighted to be sharing with you the CRASH-3 trial results.

The CRASH-3 trial results show evidence that Tranexamic Acid (TXA) can help prevent premature death from isolated Traumatic Brain Injury (TBI), a huge global health problem, and worldwide killer of thousands.

TXA must be administered as soon as possible from when an injury occurs. Every 15 minutes treatment is delayed the survival benefit from TXA drops by 10%.


The CRASH-3 trial investigated the effects of tranexamic acid on death, disability, vascular occlusive events, and other morbidities in patients with acute traumatic brain injury (CRASH-3) and was a randomised, placebo-controlled trial

The CRASH-3 trial is the first evidence of a drug that can prevent death following TBI. TXA is a safe, low-cost, and widely available drug that could prevent deaths from TBI by as much as 20% depending on the severity of the injury.

Worldwide, over 10 million people are killed or hospitalised because of TBI each year. Approximately 90% of deaths from TBI occur in low and middle-income countries. TBI predominantly affects young adults and many patients experience long-lasting or permanent disability. The social and economic burden of TBI is considerable. With rapidly increasing motorisation, the incidence of TBI is predicted to rise in low and middle-income countries. An effective, widely practicable, and affordable treatment for TBI could save many thousands of lives and could substantially reduce the burden of disability.

The CRASH-3 trial results show evidence that TXA can help prevent premature death from isolated TBI.

For more information on CRASH-3 Results head to the trial website.

Read the CRASH-3 Trial published by The Lancet HERE


Want to learn more?

Listen below to hear more about CRASH-3 and how TXA could be a potentially life-saving treatment where Pam Foley shares her story on suffering a TBI after falling off her bike and was asked to participate in the CRASH-3 trial.

Professor in Epidemiology, Ian Roberts, speaks about the effects of TXA on death, disability, vascular occlusive events, and other morbidities in patients with acute TBI and CRASH-3 on the Neurocritical Care Society podcast series.

About The Author